Harrow, Inc. (NASDAQ:HROW) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN decreased its position in Harrow, Inc. (NASDAQ:HROW) by 18.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,271 shares of the company’s stock after selling 3,151 shares during the period. Wells Fargo & Company MN’s holdings in Harrow were worth $479,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of HROW. Vanguard Group Inc. grew its stake in Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock valued at $62,809,000 after acquiring an additional 5,225 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Harrow by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock worth $8,563,000 after purchasing an additional 3,589 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Diametric Capital LP lifted its stake in Harrow by 49.0% in the 4th quarter. Diametric Capital LP now owns 110,295 shares of the company’s stock valued at $3,700,000 after buying an additional 36,269 shares in the last quarter. Finally, Trexquant Investment LP increased its stake in Harrow by 1,806.8% during the 4th quarter. Trexquant Investment LP now owns 94,500 shares of the company’s stock worth $3,170,000 after buying an additional 89,544 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. B. Riley reduced their target price on shares of Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Harrow in a report on Monday, March 31st.

Harrow Price Performance

Shares of HROW opened at $25.83 on Friday. The firm has a market capitalization of $920.94 million, a price-to-earnings ratio of -27.48 and a beta of 0.46. The firm’s fifty day simple moving average is $25.08 and its 200-day simple moving average is $33.78. Harrow, Inc. has a twelve month low of $10.08 and a twelve month high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. Equities analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.